<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468871</url>
  </required_header>
  <id_info>
    <org_study_id>415-002</org_study_id>
    <nct_id>NCT00468871</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy</brief_title>
  <official_title>A Multicenter, Randomized, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide (0.5mg) Implant Compared to Standardized Therapy in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3 year,superiority, multicenter, open-label, randomised controlled safety and
      efficacy study. The aim of this study is to evaluate the effect of an intravitreal
      fluocinolone acetonide (0.59 mg) implant compared to standardized therapy in subjects with
      unilateral or bilateral, non-infectious uveitis affecting the posterior segment of the eye.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first occurrence of uveitis in the study eye.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with a visual acuity improvement of more than 15 letters on ETDRS charts from baseline.</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of recurrences</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of recurrences compared to the 52 weeks prior to enrollment</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life indices</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjunctive treatment required</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the size, if present at baseline, of the area of CME on fluorescein angiography</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of safety variables</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects who had at least one recurrence</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Non-infectious Uveitis</condition>
  <arm_group>
    <arm_group_label>Fluocinolone acetonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal fluocinolone acetonide implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluocinolone acetonide intravitreal implant</intervention_name>
    <description>surgical intravitreal implant of fluocinolone acetonide</description>
    <arm_group_label>Fluocinolone acetonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corticosteroids and immunosuppressants</intervention_name>
    <description>Systemic corticosteroids alone or combined with immunosuppressants</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and non-pregnant females at least 6 years of age

          -  History of recurrent unilateral or asymmetric non-infectious posterior uveitis of at
             east 1 year duration not associated with significant systemic activity of the disease

          -  The more severely affected eye having had at least 2 separate recurrences

          -  The more severely affected eye having been treated by systemic therapy for at least
             one month just before inclusion

          -  Visual acuity (VA) of at least 1.4 logMAR units at enrollment

          -  At time of enrollment, &lt;/=10 anterior chamber cells/HPF and vitrous haze&lt;/= grade 2.

        Exclusion Criteria:

          -  known allergy or contraindication to fluocinolone acetonide, systemic corticosteroids,
             or the immunosuppressive agents to be administered

          -  history of retinal detachment, retinoschisis in the area of implantation, or media
             opacity precluding evaluation of the retina and vitreous

          -  presence or history of uncontrolled IOP while on steroid therapy resulting in loss of
             vision, or IOP &gt;25 mm Hg requiring at least 2 types of antiglaucoma medication to be
             reduced to &lt;25 mm Hg

          -  history of NIPU only or iritis only with no vitritis, macular edema, vitreous cells,
             or vitreous haze

          -  infectious etiology, vitreous hemorrhage, or a toxoplasma scar in the study eye

          -  ocular surgery and/or trauma on the study eye within 3 months prior to enrollment, or
             trabeculoplasty or yttrium aluminum garnet laser within 1 month prior to study
             enrollment

          -  monocularity

          -  AIDS

          -  pregnancy/lactation

          -  potential for noncompliance

          -  or participation in other clinical studies within 1 month of enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Pavesio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Retina Service/Moorfields Eye Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006 Jun;113(6):1020-7. Epub 2006 May 9.</citation>
    <PMID>16690128</PMID>
  </reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2007</study_first_submitted>
  <study_first_submitted_qc>May 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2007</study_first_posted>
  <last_update_submitted>December 7, 2011</last_update_submitted>
  <last_update_submitted_qc>December 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Fluocinolone Acetonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

